Unfortunately, the overexpression of Akt and c‐Met has not been confirmed in clinical sorafenib‐resistant HCC specimens, and the therapeutic effects of dual inhibition of Akt and Met have not been evaluated in patient‐derived xenografts, which are the limitations of the present study. Here, AKT1 is linked to hepatocellular carcinoma.